Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis
- PMID: 16449273
- PMCID: PMC2104610
- DOI: 10.1136/thx.2005.045930
Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis
Abstract
Background: The MOSAIC study compared moxifloxacin with three standard antibiotic regimens in patients with Anthonisen type 1 acute exacerbations of chronic bronchitis (AECB). Further exploratory analyses were performed to identify prognostic factors of short and long term clinical outcomes and their value for clinical research.
Methods: Outpatients aged > or =45 years were screened between AECB episodes, randomised to treatment upon presenting with an AECB, assessed 7-10 days after study treatment, and followed monthly until a new AECB or for up to 9 months. Logistic regression assessed the predictive factors for clinical cure (return to pre-AECB status) and clinical success (cure or improvement), and a stepwise Cox regression model time to a composite event (failure of study treatment, new AECB, or further antibiotic treatment for AECB).
Results: In multivariate analyses, clinical cure was positively influenced by treatment with moxifloxacin (odds ratio (OR) 1.49; 95% CI 1.08 to 2.04) while cardiopulmonary disease (OR 0.59; 95% CI 0.38 to 0.90), forced expiratory volume in 1 second (FEV1) <50% predicted (OR 0.48; 95% CI 0.35 to 0.67), and > or =4 AECBs in the previous year (OR 0.68; 95% CI 0.48 to 0.97) predicted a poorer outcome. For clinical success, treatment with moxifloxacin had a positive influence (OR 1.57; 95% CI 1.03 to 2.41) while cardiopulmonary disease (OR 0.41; 95% CI 0.25 to 0.68) and use of acute bronchodilators (OR 0.50; 95% CI 0.30 to 0.84) predicted a poorer outcome. The occurrence of the composite event was influenced by antibiotic treatment (hazard ratio (HR) 0.82; 95% CI 0.68 to 0.98), age > or =65 years (HR 1.22; 95% CI 1.01 to 1.47), FEV1<50% predicted (HR 1.27; 95% CI 1.05 to 1.53), > or =4 AECBs in previous year (HR 1.63; 95% CI 1.34 to 1.99), and acute bronchodilator use (HR 1.48; 95% CI 1.17 to 1.87). For the composite event the beneficial effect of moxifloxacin was primarily seen in patients aged > or =65 years.
Conclusion: Despite selection of a homogeneous population of patients with chronic bronchitis, between group differences relating to antibiotic treatment could still be confounded by factors related to medical history, severity of disease, and use of concomitant medications. The design of future clinical trials should take these factors into account.
Conflict of interest statement
Robert Wilson, Paul Jones and Tom Schaberg have acted as consultants and developed presentations for the sponsor for which they have received honoraria. Pierre Arvis, Isabelle Duprat‐Lomon and Pierre‐Philippe Sagnier are sponsor staff members.
Similar articles
-
Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis.Chest. 2004 Mar;125(3):953-64. doi: 10.1378/chest.125.3.953. Chest. 2004. PMID: 15006954 Clinical Trial.
-
Identifying patients at risk of late recovery (≥ 8 days) from acute exacerbation of chronic bronchitis and COPD.Respir Med. 2012 Sep;106(9):1258-67. doi: 10.1016/j.rmed.2012.06.002. Epub 2012 Jun 30. Respir Med. 2012. PMID: 22749710 Clinical Trial.
-
Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.Int J Antimicrob Agents. 2007 Jan;29(1):56-61. doi: 10.1016/j.ijantimicag.2006.08.043. Int J Antimicrob Agents. 2007. PMID: 17189096 Clinical Trial.
-
Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies.Thorax. 2008 May;63(5):415-22. doi: 10.1136/thx.2007.090613. Epub 2008 Jan 30. Thorax. 2008. PMID: 18234905 Review.
-
Appropriate outpatient treatment of acute bacterial exacerbations of chronic bronchitis.Am J Med. 2005 Jul;118 Suppl 7A:39S-44S. doi: 10.1016/j.amjmed.2005.05.012. Am J Med. 2005. PMID: 15993676 Review.
Cited by
-
Appropriate antibiotic management of bacterial lower respiratory tract infections.F1000Res. 2018 Jul 23;7:F1000 Faculty Rev-1121. doi: 10.12688/f1000research.14226.1. eCollection 2018. F1000Res. 2018. PMID: 30079235 Free PMC article. Review.
-
Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI).BMC Pulm Med. 2013 Jan 23;13:5. doi: 10.1186/1471-2466-13-5. BMC Pulm Med. 2013. PMID: 23343427 Free PMC article. Clinical Trial.
-
Epidemiology and management of common pulmonary diseases in older persons.J Gerontol A Biol Sci Med Sci. 2012 Mar;67(3):276-91. doi: 10.1093/gerona/glr251. Epub 2012 Feb 15. J Gerontol A Biol Sci Med Sci. 2012. PMID: 22337938 Free PMC article. Review.
-
Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD.Int J Chron Obstruct Pulmon Dis. 2007;2(3):191-204. Int J Chron Obstruct Pulmon Dis. 2007. PMID: 18229559 Free PMC article. Review.
-
The problems of meta-analysis for antibiotic treatment of chronic obstructive pulmonary disease, a heterogeneous disease: a commentary on Puhan et al.BMC Med. 2008 Oct 10;6:29. doi: 10.1186/1741-7015-6-29. BMC Med. 2008. PMID: 18847482 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical